Generated by AI
Pacira BioSciences, Inc. is a specialty biopharmaceutical company focused on non-opioid pain management and regenerative health solutions. Pacira BioSciences develops, manufactures, markets, distributes, and sells therapies used across postsurgical, chronic, and musculoskeletal pain settings, serving healthcare practitioners in the United States. Its commercial portfolio includes EXPAREL, a long-acting local anesthetic used in surgical pain control, ZILRETTA, an extended-release injectable treatment for knee osteoarthritis pain, and iovera°, a handheld device that delivers targeted cold therapy for drug-free pain relief. The company also advances pipeline programs such as PCRX-201, a locally administered gene therapy candidate being studied for osteoarthritis of the knee. Pacira BioSciences plays a notable role in the pain-treatment market by offering alternatives designed to reduce reliance on opioids while supporting patient recovery and function.
Website2000 Sierra Point Parkway
Brisbane, CA, 94005
United States
The latest articles about PCRX.
Summary of Oct 11's posts. Generated by AI.
Summary of Oct 8's posts. Generated by AI.
Summary of Oct 8's posts. Generated by AI.
Summary of Oct 11's posts. Generated by AI.
Investors talking about PCRX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.